Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 9/20 | 0.58 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.41 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.41 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.41 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16011302 | 1.00 | ACVRL1 (0.58) | ACVRL1TYRO3AXLCSNK2A2CSNK2A1 | |
| SCHEMBL31391141 | 0.93 | ACVRL1 (0.49) | ACVRL1TYRO3AXLMTORRICTOR | |
| SCHEMBL19429526 | 0.86 | ACVRL1 (0.45) | ACVRL1CSNK2A2CSNK2A1MTORRICTOR | |
| SCHEMBL19377710 | 0.85 | ACVRL1 (0.44) | ACVRL1TYRO3AXLMTORRICTOR | |
| SCHEMBL19377805 | 0.83 | PIK3CD (0.53) | ACVRL1TYRO3AXLCSNK2A2CSNK2A1 | |
| SCHEMBL19377690 | 0.83 | ACVRL1 (0.61) | ACVRL1TYRO3MTORRICTORRPTOR | |
| SCHEMBL5080198 | 0.83 | ACVRL1 (0.46) | ACVRL1TYRO3AXLCSNK2A2CSNK2A1 | |
| SCHEMBL19377514 | 0.83 | TYRO3 (0.44) | ACVRL1TYRO3MTORRICTORRPTOR | |
| SCHEMBL19377687 | 0.82 | PIK3CD (0.56) | ACVRL1TYRO3CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL19429748 | 0.82 | PIK3CD (0.47) | ACVRL1TYRO3AXLCSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534479-B2 | Triazine compound and composition and use thereof | FINDCURE BIOSCIENCES (ZHONGSHAN) CO., LTD. (CN) | 2026-01-27 | — | — | US | disclosed |
| US-20230279024-A1 | TRIAZINE COMPOUND AND COMPOSITION AND USE THEREOF | BEIJING FINDCURE BIOSCIENCES, LTD. (CN) | 2023-09-07 | — | — | US | disclosed |
| EP-4180433-A1 | TRIAZINE COMPOUND AND COMPOSITION AND USE THEREOF | Beijing Findcure Biosciences, Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| EP-2726482-B1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER IP GMBH (DE) | 2016-07-20 | — | — | EP | disclosed |
| CN-103764657-B | The pyrrolo-triazine replacing as the methylol aryl of ALK1 inhibitor | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-25 | — | — | CN | disclosed |
| US-9040691-B2 | Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-9040691-B2 | Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-9040691-B2 | Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-20140256718-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| US-20140256718-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| US-20140256718-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534479-B2 | Triazine compound and composition and use thereof | JAK1, CCR1, PEAK1 | ACVRL1 1619/4885TYRO3 456/4885AXL 2111/4885 |
| US-20140256718-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | ALK, FLT1, ACVR1 | ACVRL1 4/4885TYRO3 135/4885AXL 645/4885 |
| US-20230279024-A1 | TRIAZINE COMPOUND AND COMPOSITION AND USE THEREOF | JAK1, MAP3K5, MAP3K15 | ACVRL1 1152/4885TYRO3 115/4885AXL 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.